ARTICLE IN ACADEMIC JOURNALS
| NO | DETAILS OF ARTICLE IN ACADEMIC JOURNALS |
|---|---|
| 1. |
Loss-of-Function Variant in the SMPD1 Gene in Progressive Supranuclear Palsy-Richardson Syndrome Patients of Chinese Ancestry
2024
Source :
JOURNAL OF MOVEMENT DISORDERS
DOI :
10.14802/jmd.24009
|
| 2. |
Genetic study of early-onset Parkinson's disease in the Malaysian population
2023
Source :
PARKINSONISM & RELATED DISORDERS
DOI :
10.1016/j.parkreldis.2023.105399
|
| 3. |
New insights from a multi-ethnic Asian progressive supranuclear palsy cohort
2023
Source :
PARKINSONISM & RELATED DISORDERS
DOI :
10.1016/j.parkreldis.2023.105296
|
| 4. |
Genetics Matters: Voyaging from the Past into the Future of Humanity and Sustainability
2022
Source :
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
DOI :
10.3390/ijms23073976
|
| 5. |
Facile synthesis of biocompatible sub-5 nm alginate-stabilised gold nanoparticles with sonosensitising properties
2021
Author(s) : Chung Lip Yong, Kiew Lik Voon, Zamri Bin Chik, Teo Yin Yin, Lit Lei Cheng, Leo Bey Fen, Foo Yiing Yee, Muhammad Farid Nazer Bin Muhammad Faruqu Source :
COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
DOI :
10.1016/j.colsurfa.2021.127141
|
| 6. |
Clinical phenotype of Parkinson's disease with a homozygous PRKN p.Cys441Arg mutation
2021
Source :
NEUROLOGY ASIA
|
| 7. |
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth (vol 31, pg 2103, 2015)
2021
Author(s) : Lit Lei Cheng Source :
ONCOGENE
DOI :
10.1038/s41388-021-01759-9
|
| 8. |
LMTK-3 confers chemo-resistance in breast cancer.
2018
Author(s) : Cheah Swee Hung, Justin Stebbing, Kalpit Shah, Teresa Gagliano, Angeliki Ditsiou, Tingting Wang, Franz Wendler, Thomas Simon, Krisztina Szabo, Timothy O'hanlon, Michael Dean, Lit Lei Cheng, April Camilla Roslani Source :
Oncogene
DOI :
10.1038/s41388-018-0197-0
|
| 9. |
KSR1 regulates BRCA1 degradation and inhibits breast cancer growth
2015
Author(s) : Lit Lei Cheng Source :
Oncogene
|
| 10. |
The regulatory roles of phosphatases in cancer
2014
Author(s) : Lit Lei Cheng Source :
Oncogene
|
| 11. |
The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin
2014
Author(s) : Lit Lei Cheng Source :
Science Signaling
|
| 12. |
LMTK3 is implicated in endocrine resistance via multiple signaling pathways
2013
Author(s) : Lit Lei Cheng Source :
Oncogene
|
| 13. |
LATS2 is a modulator of estrogen receptor alpha
2013
Author(s) : Lit Lei Cheng Source :
Anticancer Research
|
| 14. |
SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1
2013
Author(s) : Lit Lei Cheng Source :
British Journal of Cancer
|
PROCEEDING
| NO | DETAILS OF PROCEEDING |
|---|---|
| 1. |
The role of LMTK3 in breast cancer cell growth and invasion
2013
Author(s) : Lit Lei Cheng |
| 2. |
Aqueous extract of Rodgersia sambucifolia suppress on the natural killer cell activity in normal subjects and recurrent spontaneous aborters
2010
Author(s) : Lit Lei Cheng |
| 3. |
Workshop on Isolated Tissue Preparations and HPLC
2007
Author(s) : Lit Lei Cheng |
RESEARCH PROJECT
| GRANT | PROGRESS | STATUS |
|---|---|---|
|
Investigating Mitochondrial Dysfunction As A Mechanism Of Fat Loss In Parkinson?s Disease
|
|
end |
|
Understanding The Mechanism Of Extracellular Release Of ?-synuclein Through Leucine-rich Repeat Kinase 2 (lrrk2) Mutations And Kinase Inhibition
Researcher(s) : Prof. Dr. Lim Shen-yang, Dr. Chee Chin Fei, Associate Prof. Dr. Tan Ai Huey, Dr. Chin Sek Peng |
|
end |
RESEARCH COLLABORATOR
| GRANT | PROGRESS | STATUS |
|---|---|---|
|
Identifying Leucocyte And Urine Biomarkers In Pd Patients With Lrrk2 G2385r Variant
|
|
on going |
|
Development Of Ultrasound-responsive-biostealth-nano-pouch For Effective Delivery And Controlled-release Of Tumour Penetrating Metallic Nanoparticles
Researcher(s) : Prof. Dr. Chung Lip Yong, Prof. Dr. Misni Bin Misran, Associate Prof. Dr. Leo Bey Fen, Associate Prof. Dr. Teo Yin Yin, Dr. Lit Lei Cheng, Dr. Foo Yiing Yee, Chia-ching Chang, Zhan Yuin Ong |
|
end |
|
Development Of Highly Potent, Selective, And Brain-penetrant Aminopyridoxamine Leucine-rich Repeat Kinase 2 (lrrk2) Inhibitors For Parkinson S Disease Treatment
|
|
end |